Jean Francois Formela sold $2.5M of KRRO
director at Korro Bio, Inc.. 171,405 shares at an average of $14.34, traded Jun 22, 2026, filed Jun 24, 2026.
Score components
- +15RoleDirector
- +25Trade size$2.5M at market
- +5Share of holdings soldSold 18% of holdings
- +15Cluster5 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001030575-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 22, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -3,382 | $13.95 | $47k | 936,252 | Jun 24, 2026 |
| Jun 22, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -580 | $13.95 | $8,091 | 194,075 | Jun 24, 2026 |
| Jun 23, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -101,579 | $14.25 | $1.4M | 834,673 | Jun 24, 2026 |
| Jun 23, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -17,426 | $14.25 | $248k | 176,649 | Jun 24, 2026 |
| Jun 24, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -40,679 | $14.60 | $594k | 793,994 | Jun 24, 2026 |
| Jun 24, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -666 | $14.98 | $9,977 | 793,328 | Jun 24, 2026 |
| Jun 24, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -6,979 | $14.60 | $102k | 169,670 | Jun 24, 2026 |
| Jun 24, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -114 | $14.98 | $1,708 | 169,556 | Jun 24, 2026 |
Related signals
Other insiders at Korro Bio, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 24Weak | Korro Bio, Inc. | Jean Francois Formela director | $686k 48,690 shares | -7% | |
| 3Weak | Korro Bio, Inc. | Oliver Dolan Senior Vice President, Finance | $69 5 shares | -0% | |
| 23Weak | Korro Bio, Inc. | Oliver Dolan Senior Vice President, Finance | $99k 7,353 shares | -31% | |
| 3Weak | Korro Bio, Inc. | Jean Francois Formela director | $4,188 300 shares | -0% | |
| 11Weak | Korro Bio, Inc. | Jean Francois Formela director | $399k 28,468 shares | -4% | |
| 8Weak | Korro Bio, Inc. | Jean Francois Formela director | $30k 2,143 shares | -0% | |
| 24Weak | KRRObuy Korro Bio, Inc. | Lynx1 Capital Management LP owner | $79k 6,684 shares | +0% | |
| 41Moderate | Korro Bio, Inc. | Ram Aiyar President and CEO | $63k 5,802 shares | -8% | |
| 25Weak | Korro Bio, Inc. | Jean Francois Formela director | $1.5M 110,023 shares | -14% | |
| 43Moderate | Korro Bio, Inc. | Jeffrey Cerio General Counsel | $72k 6,609 shares | -16% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.